Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beximco Launches World’s First Molnupiravir Generic

Generic Version Of MSD’s Oral Therapy For COVID-19 To Be Marketed As Emorivir

Executive Summary

Bangladesh’s Beximco has launched the world’s first molnupiravir generic, to be marketed as Emorivir, following an emergency use authorization by the local regulator. The company told Generics Bulletin it was able to manufacture and sell its version of the MSD oral COVID-19 treatment thanks to the WTO’s TRIPS waiver for less economically developed countries.

You may also be interested in...



EMA Confirms Fast-Track EUA-Style Review For Molnupiravir In COVID-19

The EU regulator says it is taking the emergency use route for molnupiravir because of the worrying rise in coronavirus infections and deaths.

EMA Considers EUA-Style Fast Track Decision For Molnupiravir

The European Medicines Agency is considering making a rapid recommendation on MSD’s molnupiravir in order to speed access to the potential ‘game changer’ COVID-19 pill.

MSD's COVID-19 Pill Molnupiravir Gains First Approval In UK

The UK becomes the first country to grant a marketing authorization for the oral treatment which could help cut hospitalizations and deaths by half.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151396

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel